KRYS vs. SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, QGEN, and ASND
Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Krystal Biotech vs.
Summit Therapeutics (NASDAQ:SMMT) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
Krystal Biotech has a net margin of 30.69% compared to Summit Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 11.41% beat Summit Therapeutics' return on equity.
Summit Therapeutics presently has a consensus price target of $33.57, suggesting a potential upside of 45.58%. Krystal Biotech has a consensus price target of $210.00, suggesting a potential upside of 14.99%. Given Summit Therapeutics' higher possible upside, equities research analysts plainly believe Summit Therapeutics is more favorable than Krystal Biotech.
Krystal Biotech has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics received 10 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 67.51% of users gave Krystal Biotech an outperform vote while only 58.38% of users gave Summit Therapeutics an outperform vote.
4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summit Therapeutics has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
In the previous week, Krystal Biotech had 22 more articles in the media than Summit Therapeutics. MarketBeat recorded 26 mentions for Krystal Biotech and 4 mentions for Summit Therapeutics. Krystal Biotech's average media sentiment score of 0.90 beat Summit Therapeutics' score of 0.44 indicating that Krystal Biotech is being referred to more favorably in the news media.
Summary
Krystal Biotech beats Summit Therapeutics on 14 of the 18 factors compared between the two stocks.
Get Krystal Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Krystal Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:KRYS) was last updated on 2/21/2025 by MarketBeat.com Staff
Free KRYS Stock Alerts